What action is the Welsh Government taking to ensure that the NHS in Wales has the resources and infrastructure to deliver the use of Ocrelizumab to treat multiple sclerosis?
The updated Neurological Conditions Delivery Plan sets out our vision for improving neurological services across Wales, more effectively and at a greater pace, in conjunction with Health Boards’ local vision for their resident population and aligned with Integrated Medium Term Plans.
The actions within the plan promote a collaborative approach to the treatment of all neurological conditions including multiple sclerosis and are monitored by the Neurological Conditions Implementation Group (NCIG). The NCIG works to ensure that those affected by any kind of neurological condition have timely access to high quality pathways of care and the most effective treatments are available for people wherever they live throughout Wales.
Ocrelizumab has been routinely available as an option for treating relapsing–remitting multiple sclerosis in Wales since 2018. Ocrelizumab will be made available for primary progressive multiple sclerosis within 60 days of the manufacturer agreeing the terms of the commercial agreement endorsed by NICE with the NHS in Wales. Implementation will be closely monitored in conjunction with the NCIG.